Blurbs

Analysts Offer Insights on Healthcare Companies: ObsEva SA (OBSV), Bionomics Ltd ADR (BNOX) and Xilio Therapeutics (XLO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSVResearch Report), Bionomics Ltd ADR (BNOXResearch Report) and Xilio Therapeutics (XLOResearch Report) with bullish sentiments.

ObsEva SA (OBSV)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA, with a price target of $15.00. The company’s shares closed last Friday at $1.94, close to its 52-week low of $1.93.

According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

ObsEva SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.

See Insiders’ Hot Stocks on TipRanks >>

Bionomics Ltd ADR (BNOX)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Bionomics Ltd ADR, with a price target of $54.00. The company’s shares closed last Friday at $11.55.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -8.7% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bionomics Ltd ADR with a $54.00 average price target.

Xilio Therapeutics (XLO)

In a report released today, Michael King from H.C. Wainwright initiated coverage with a Buy rating on Xilio Therapeutics and a price target of $36.00. The company’s shares closed last Friday at $14.32.

According to TipRanks.com, King is a 4-star analyst with an average return of 17.6% and a 49.2% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics.

Currently, the analyst consensus on Xilio Therapeutics is a Strong Buy with an average price target of $34.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OBSV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed